Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theralase Technologies Inc (OP: TLTFF )

0.1258 -0.0055 (-4.19%)
Streaming Delayed Price Updated: 3:34 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,500
Open 0.1274
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1313
Today's Range 0.1211 - 0.1306
52wk Range 0.0800 - 0.2000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
Via ACCESSWIRE
Theralase(R) Extends Warrants
Via ACCESSWIRE

Performance

YTD
-9.56%
-9.56%
1 Month
-3.60%
-3.60%
3 Month
-5.41%
-5.41%
6 Month
+5.89%
+5.89%
1 Year
-23.57%
-23.57%

More News

Read More
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
Via ACCESSWIRE
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
Via ACCESSWIRE
Theralase(R) Release’s 2Q2024 Financial Statements
Via ACCESSWIRE
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
Via ACCESSWIRE
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
Via ACCESSWIRE
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
Via ACCESSWIRE
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
Via ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy
Via ACCESSWIRE
Ruvidar(TM) Enhances Efficacy of Cancer Drug
Via ACCESSWIRE
Theralase(R) Successfully Destroys Lung Cancer
Via ACCESSWIRE
Theralase(R) Technology Effective in Virus Inactivation
Via ACCESSWIRE
Theralase(R) Release's 1Q2024 Financial Statements
Via ACCESSWIRE
Theralase(R) Expands Clinical Team
Via ACCESSWIRE
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
Via ACCESSWIRE
Theralase(R) Granted Canadian Cancer Vaccine Patent
Via ACCESSWIRE
Theralase(R) Release's 4Q2023 Interim Financial Statements
Via ACCESSWIRE
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
Via ACCESSWIRE
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
Via ACCESSWIRE
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Via ACCESSWIRE
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
Via ACCESSWIRE
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.